Celyad Oncology Announces Appointment of Matt Kane as Chief Executive Officer [Yahoo! Finance]
Precision BioSciences, Inc. (DTIL)
Last precision biosciences, inc. earnings: 11/12 07:15 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad") is pleased to announce Matt Kane as its new Chief Executive Officer (CEO), effective as of October 1 st Matt Kane is a seasoned executive with over 20 years of experience in entrepreneurial, CEO and board roles. Mr. Kane is a pioneer in genome editing, led the development of the first editing technology to receive clearance for clinical evaluation as an in vivo gene insertion therapeutic and, most importantly, led the development and clinical testing of multiple allogeneic chimeric antigen receptor (CAR) T-cell therapies directed against cancer. His extensive scientific and business acumen have been demonstrated during his career by raising over $500M in equity financings and partnerships valued at over $4B. Mr. Kane is currently involved with several entrepreneurial initiatives within the biotechnology industry. Until recently, he served as CEO and board member of Tune Therapeutics, Inc an epigenetic editing biotechnol
Show less
Read more
Impact Snapshot
Event Time:
DTIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DTIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DTIL alerts
High impacting Precision BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
DTIL
News
- Precision BioSciences to Participate in Upcoming November Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Precision BioSciences to Participate in Upcoming November Investor ConferencesBusiness Wire
- Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B [Yahoo! Finance]Yahoo! Finance
- Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis BBusiness Wire
- Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
DTIL
Earnings
- 11/4/24 - Miss
DTIL
Sec Filings
- 11/21/24 - Form 4
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- DTIL's page on the SEC website